# A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

Source: https://onco.cc/trials/nct07597629/  
OnCo record `nct07597629` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.

## Summary

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer is a phase 2 interventional study registered as NCT07597629 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 36 participants planned, started 2026-05-25 and due to reach its primary completion in 2027-11-30. Interventions recorded: SYS6023 and KN026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07597629
- Phase: 2
- Setting: A Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6023 Combination Therapy for Unresectable Locally Advanced or Metastatic Breast Cancer
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07597629: https://clinicaltrials.gov/study/NCT07597629

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [KN026](https://onco.cc/drugs/kn026/), [SYS6023](https://onco.cc/drugs/sys6023/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07597629.json